05 — Treatment Pathways
Table of Contents
1.0 Treatment Philosophy
The Sandusky Dyslipidemia Model follows a “lower is better” philosophy grounded in the totality of evidence from randomized trials, Mendelian randomization studies, and meta-analyses demonstrating a continuous, log-linear relationship between LDL-C exposure and ASCVD risk without a lower threshold of benefit [1, 2, 3].
1.1 Core Principles
- Guideline adherence first: All treatment decisions are anchored in the 2026 ACC/AHA/Multisociety Guidelines [4]. Guideline-recommended LDL-C thresholds are the minimum acceptable targets.
- ApoB as an intensification trigger: When ApoB exceeds risk-appropriate targets despite LDL-C at guideline goal, treatment intensification is warranted.
- Treat the particle, not just the cholesterol: LDL-C is the primary metric; ApoB and LDL-P serve as secondary metrics to identify residual atherogenic burden.
- No lower limit for benefit: The clinic does not withhold intensification based on “LDL-C is already low enough” if ApoB remains above target and the patient tolerates therapy.
1.2 Treatment Targets by Risk Category
| Risk Category | LDL-C Target | ApoB Target | Non-HDL-C Target |
|---|---|---|---|
| Low | < 130 mg/dL | < 100 mg/dL | < 160 mg/dL |
| Borderline | < 130 mg/dL | < 100 mg/dL | < 160 mg/dL |
| Intermediate | < 100 mg/dL | < 90 mg/dL | < 130 mg/dL |
| High | < 70 mg/dL | < 80 mg/dL | < 100 mg/dL |
| Very High (ASCVD) | < 55 mg/dL | < 65 mg/dL | < 85 mg/dL |
These are minimum targets. Per the “lower is better” philosophy, lower achieved levels are preferred if tolerated. ApoB above target despite LDL-C at goal is an indication for further intensification.
2.0 Lifestyle Modification
Lifestyle modification is recommended for all patients as an adjunct to pharmacotherapy. This clinic does not provide formal dietary counseling or exercise prescription services; these are discussed during the provider encounter and patients are referred to appropriate resources as needed.
2.1 Key Lifestyle Recommendations
| Intervention | Expected LDL-C Reduction | Notes |
|---|---|---|
| Heart-healthy dietary pattern (Mediterranean, DASH, or portfolio diet) | 10–15% | Emphasize vegetables, fruits, whole grains, lean protein, nuts, olive oil [5] |
| Reduce saturated fat to < 6% of total calories | 8–10% | Replace with unsaturated fats [4] |
| Increase dietary soluble fiber (10–25 g/day) | 5–10% | Oats, barley, legumes, psyllium |
| Regular aerobic exercise (150 min/week moderate or 75 min/week vigorous) | 3–5% LDL-C; raises HDL-C | Per AHA physical activity guidelines [6] |
| Weight management (achieve/maintain BMI 18.5–24.9) | Variable | Reduces TG, improves insulin sensitivity, may modestly reduce LDL-C |
| Smoking cessation | Minimal direct LDL-C effect | Reduces ASCVD risk independently; improves HDL-C [4] |
2.2 Limitations
- Lifestyle modification alone is insufficient for most patients referred to this clinic, given the severity of their dyslipidemia and/or risk profile.
- Lifestyle changes should not delay initiation of pharmacotherapy in high-risk or very high-risk patients.
Nutraceuticals such as plant sterols/stanols, red yeast rice, bergamot, berberine, and omega-3 supplements are not included in this clinic’s therapeutic plan.
3.0 Statin Therapy
Statins are the foundation of LDL-C lowering therapy and the first-line pharmacological treatment for most patients [4].
3.1 Statin Intensity
| Intensity | Expected LDL-C Reduction | Agents and Doses |
|---|---|---|
| High | ≥ 50% | Atorvastatin 40–80 mg; Rosuvastatin 20–40 mg |
| Moderate | 30–49% | Atorvastatin 10–20 mg; Rosuvastatin 5–10 mg; Simvastatin 20–40 mg; Pravastatin 40–80 mg; Lovastatin 40–80 mg; Fluvastatin 80 mg XL; Pitavastatin 1–4 mg |
| Low | < 30% | Simvastatin 10 mg; Pravastatin 10–20 mg; Lovastatin 20 mg; Fluvastatin 20–40 mg |
3.2 Statin Selection by Risk Category
| Risk Category | Recommended Intensity | Preferred Agents |
|---|---|---|
| Very high (ASCVD) | High-intensity | Atorvastatin 80 mg or Rosuvastatin 40 mg |
| High | High-intensity | Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg |
| Intermediate | Moderate-to-high intensity | Atorvastatin 10–40 mg or Rosuvastatin 10–20 mg |
| Borderline (if initiating) | Moderate intensity | Atorvastatin 10–20 mg or Rosuvastatin 5–10 mg |
3.3 Statin Monitoring
| Parameter | Timing |
|---|---|
| Lipid panel | 4–8 weeks after initiation/dose change, then per follow-up cadence |
| Hepatic transaminases (ALT) | Baseline; repeat only if symptoms suggest hepatotoxicity |
| Creatine kinase (CK) | Not routinely monitored; check if patient reports myalgia |
| HbA1c / fasting glucose | Periodically in patients at risk for diabetes (statins modestly increase diabetes incidence) [7] |
3.4 Statin Intolerance
For patients reporting statin intolerance, see the dedicated pathway: 08 — Statin Intolerance.
4.0 Ezetimibe
Ezetimibe inhibits intestinal cholesterol absorption via the NPC1L1 transporter and provides an additional 15–20% LDL-C reduction when added to statin therapy [8].
4.1 Indications
| Indication | Notes |
|---|---|
| LDL-C not at goal on maximally tolerated statin | First add-on agent per 2026 guidelines [4] |
| Statin-intolerant patient | Monotherapy or in combination with bempedoic acid |
| Any risk category requiring additional LDL-C lowering | Well-tolerated with favorable safety profile |
4.2 Dosing
- Ezetimibe 10 mg daily (single dose; only available dose)
- May be taken with or without food
- Available as a fixed-dose combination with simvastatin (Vytorin) — though this clinic prefers atorvastatin or rosuvastatin as the statin backbone
4.3 Evidence Base
The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin reduced cardiovascular events in post-ACS patients, with an absolute LDL-C reduction to 54 mg/dL vs. 70 mg/dL [8]. This supports the “lower is better” principle.
5.0 PCSK9 Inhibitors
PCSK9 monoclonal antibodies reduce LDL-C by 50–60% when added to statin therapy by preventing LDL receptor degradation [9, 10].
5.1 Available Agents
| Agent | Dosing | Administration |
|---|---|---|
| Evolocumab (Repatha) | 140 mg SC every 2 weeks or 420 mg SC monthly | Prefilled syringe or autoinjector; refrigerated storage |
| Alirocumab (Praluent) | 75 mg SC every 2 weeks (may increase to 150 mg if needed) | Prefilled pen; refrigerated storage |
5.2 Indications
| Indication | Supporting Evidence |
|---|---|
| Established ASCVD with LDL-C ≥ 70 mg/dL on maximally tolerated statin + ezetimibe | FOURIER [9], ODYSSEY Outcomes [10] |
| FH with LDL-C not at goal on maximally tolerated statin + ezetimibe | RUTHERFORD-2 [11] |
| Very high-risk patients requiring > 50% LDL-C reduction beyond statin + ezetimibe | Per 2026 guidelines [4] |
| Statin-intolerant patients requiring significant LDL-C lowering | GAUSS-3 [12] |
5.3 Monitoring
- Lipid panel 4–8 weeks after initiation, then per follow-up cadence
- No routine liver or CK monitoring required
- Injection site reactions: monitor and counsel
5.4 Prior Authorization
PCSK9 inhibitors typically require prior authorization. See 11 — Prior Authorization for templates and documentation requirements.
6.0 Bempedoic Acid
Bempedoic acid inhibits ATP-citrate lyase (ACL), a step upstream of HMG-CoA reductase in the cholesterol synthesis pathway. It is a prodrug activated in the liver (not in skeletal muscle), which explains the absence of myotoxicity [13].
6.1 Dosing
| Formulation | Dose | Expected LDL-C Reduction |
|---|---|---|
| Bempedoic acid (Nexletol) | 180 mg daily | 15–25% as monotherapy |
| Bempedoic acid + ezetimibe (Nexlizet) | 180 mg / 10 mg daily | 35–40% combined |
6.2 Indications
| Indication | Notes |
|---|---|
| Statin-intolerant patients | No muscle-related side effects (CLEAR Outcomes) [13] |
| Add-on therapy in patients not at goal on statin ± ezetimibe | Alternative to or bridge to PCSK9i |
| Patients declining injectable therapy | Oral alternative |
6.3 Key Safety Considerations
- Uric acid elevation: May precipitate gout in predisposed patients; monitor uric acid
- Tendon rupture: Rare reports; caution in patients on fluoroquinolones
- Renal function: Monitor creatinine; small increases reported
- CK: No significant elevations (does not activate in skeletal muscle)
6.4 Evidence Base
The CLEAR Outcomes trial demonstrated that bempedoic acid reduced major adverse cardiovascular events in statin-intolerant patients, with a 13% relative risk reduction (HR 0.87, 95% CI 0.79–0.96) [13].
7.0 Inclisiran
Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 mRNA synthesis, resulting in sustained LDL-C reduction with twice-yearly dosing [14].
7.1 Dosing
| Dose | Schedule |
|---|---|
| 284 mg SC | Day 0 → Day 90 → Every 6 months thereafter |
7.2 Indications
- Established ASCVD or FH requiring additional LDL-C reduction beyond maximally tolerated statin + ezetimibe
- Patients who prefer twice-yearly in-office injection over biweekly/monthly self-injection (PCSK9 mAb)
- Adherence concerns with daily oral or biweekly injectable medications
7.3 Expected Efficacy
- LDL-C reduction: approximately 50% when added to statin therapy [14]
- Durable effect maintained between doses
7.4 Administration
Inclisiran is administered as a subcutaneous injection by a healthcare provider (not self-administered). This aligns with the clinic’s visit structure — the injection is given during the office visit.
7.5 Prior Authorization
Inclisiran typically requires prior authorization. See 11 — Prior Authorization.
8.0 Icosapent Ethyl (Vascepa)
Icosapent ethyl is a purified eicosapentaenoic acid (EPA) ethyl ester indicated for ASCVD risk reduction in patients with elevated triglycerides [15].
8.1 Indications
Per the REDUCE-IT trial [15], icosapent ethyl is indicated for patients meeting all of the following:
| Criterion | Details |
|---|---|
| Established ASCVD or diabetes with ≥ 2 additional risk factors | High-risk population |
| Fasting triglycerides 135–499 mg/dL | Despite maximally tolerated statin therapy |
| On stable statin therapy | ≥ 4 weeks |
8.2 Dosing
- 2 g twice daily with food (total 4 g/day)
8.3 Key Safety Considerations
- Atrial fibrillation/flutter: Increased incidence (5.3% vs. 3.9% in REDUCE-IT) [15]; caution in patients with history of AF
- Bleeding: Small increased risk of bleeding; caution with anticoagulants
- Seafood/fish allergy: Purified EPA; use caution in patients with known fish allergy
8.4 Distinction from Omega-3 Supplements
Icosapent ethyl (Vascepa) is an FDA-approved prescription medication with cardiovascular outcomes data. It is distinct from over-the-counter omega-3 supplements (fish oil), which have not demonstrated ASCVD event reduction and are not part of this clinic’s therapeutic plan [16].
9.0 Fibrates
Fibrates (PPARα agonists) primarily lower triglycerides and modestly raise HDL-C. Their role in ASCVD prevention is limited.
9.1 Available Agents
| Agent | Dose | Expected TG Reduction |
|---|---|---|
| Fenofibrate (Tricor) | 145 mg daily | 30–50% |
| Fenofibric acid (Trilipix) | 135 mg daily | 30–50% |
| Gemfibrozil (Lopid) | 600 mg twice daily | 30–50% |
9.2 Indications
| Indication | Notes |
|---|---|
| Severe hypertriglyceridemia (TG ≥ 500 mg/dL) | Primary goal is pancreatitis prevention, not ASCVD reduction |
| Persistent moderate hypertriglyceridemia (TG 200–499) despite lifestyle and statin | Limited ASCVD outcomes data; consider only if TG-mediated risk is high |
9.3 Safety Considerations
- Gemfibrozil + statin: Contraindicated due to myopathy risk (inhibits statin glucuronidation) [17]
- Fenofibrate + statin: Acceptable combination; fenofibrate does not inhibit statin metabolism [17]
- Renal function: Dose-adjust fenofibrate for eGFR; may reversibly increase creatinine
- Cholelithiasis: Increased risk with fibrate therapy
10.0 Niacin (Extended-Release)
Niacin (nicotinic acid) lowers LDL-C (15–25%), triglycerides (20–50%), and Lp(a) (20–30%), and raises HDL-C (15–35%) [18].
10.1 Limited Role
The role of niacin in contemporary practice is limited by:
- AIM-HIGH [19] and HPS2-THRIVE [20] trials showed no incremental ASCVD benefit when added to statin therapy
- Significant side effects (flushing, hepatotoxicity, glucose intolerance, hyperuricemia)
- Availability of better-tolerated alternatives
10.2 Potential Niche Indications
| Scenario | Rationale |
|---|---|
| Patient with markedly elevated Lp(a) who has exhausted other options | Niacin is one of few agents that lowers Lp(a); may reduce by 20–30% [18] |
| Combined dyslipidemia not controlled by statin + ezetimibe + fibrate | Last-line option |
10.3 If Prescribed
- Use extended-release formulation only (immediate-release has higher hepatotoxicity risk)
- Start at 500 mg at bedtime; titrate by 500 mg every 4 weeks to max 2000 mg
- Pretreat with aspirin 30 minutes before dosing to reduce flushing
- Monitor hepatic function, glucose, and uric acid
11.0 Treatment Escalation Algorithm
The following stepwise approach applies to patients not at their risk-appropriate LDL-C and/or ApoB target. See the Treatment Escalation Flowchart for a visual representation.
Step 1: Maximize Statin Therapy
- Initiate or uptitrate to the highest tolerated intensity statin
- Recheck lipid panel (including ApoB if indicated) in 4–8 weeks
Step 2: Add Ezetimibe
- If LDL-C and/or ApoB not at target → add ezetimibe 10 mg daily
- Recheck in 4–8 weeks
Step 3: Add PCSK9 Inhibitor, Inclisiran, or Bempedoic Acid
- If still not at target → select based on clinical scenario:
| Agent | Preferred When |
|---|---|
| PCSK9 inhibitor (evolocumab or alirocumab) | Maximum LDL-C reduction needed (50–60% additional); ASCVD outcomes data (FOURIER, ODYSSEY) |
| Inclisiran | Adherence concerns; patient prefers in-office dosing every 6 months |
| Bempedoic acid (± ezetimibe combo) | Statin-intolerant; patient prefers oral medication; moderate additional reduction needed (15–25%) |
Step 4: Combination Advanced Therapy
- For patients not at goal on statin + ezetimibe + one advanced agent:
- Consider adding a second advanced agent (e.g., PCSK9i + bempedoic acid)
- Reassess adherence, secondary causes, and FH
Step 5: Address Residual Risk
- If LDL-C at target but ApoB remains elevated → continue intensification
- If triglycerides 135–499 mg/dL with ASCVD or high risk → consider icosapent ethyl
- If Lp(a) ≥ 125 nmol/L → maximize all modifiable risk factors; document as risk modifier
12.0 Version History
| Version | Date | Description |
|---|---|---|
| 1.0.0 | 2026-03-30 | Initial release |
References
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J. 2017;38(32):2459–2472.
- Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
- Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.
- 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026.
- Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED). N Engl J Med. 2018;378(25):e34.
- Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. JAMA. 2018;320(19):2020–2028.
- Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–742.
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387–2397.
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376(18):1713–1722.
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY Outcomes). N Engl J Med. 2018;379(22):2097–2107.
- Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2). Lancet. 2015;385(9965):331–340.
- Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance (GAUSS-3). JAMA. 2016;315(15):1580–1590.
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353–1364.
- Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol (ORION-10 and ORION-11). N Engl J Med. 2020;382(16):1507–1519.
- Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22.
- Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events (STRENGTH). JAMA. 2020;324(22):2268–2280.
- Jacobson TA. Myopathy with statin–fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009;5(9):507–518.
- Goldberg AC. A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women. Am J Cardiol. 2004;94(1):121–124.
- AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.
- HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.